Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 4.72% | 2.39% | 21.70% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 21.7% | 0.2% | 12.4% | -10.6% | 11.6% | -4.4% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 4.72% | 2.39% | 21.70% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 21.7% | 0.2% | 12.4% | -10.6% | 11.6% | -4.4% |
Tweedy, Browne's Worldwide High Dividend Yield Value Fund delivered strong absolute returns of 21.70% in 2025, driven by pharmaceutical holdings like Roche and Novartis that benefited from new drug approvals and steady earnings generation. The fund's dividend-focused strategy contributed meaningfully through financials and industrials exposure. Defense holdings like BAE Systems and Rheinmetall, while previously strong performers, declined in Q4 as valuations moved ahead of fundamentals, prompting modest position trims. Technology holdings including Samsung and Alphabet contributed positively despite price appreciation. The manager expresses concern about excessive valuations across most asset categories, particularly US equities, warning that current market exuberance driven by AI optimism may prove temporary. However, they remain confident in their positioning in financially sound international enterprises where stock prices are collateralized by intrinsic value. The significant valuation gap between US and non-US equities should benefit their non-US-centric portfolio positioning going forward.
Tweedy, Browne maintains that a diversified portfolio of well-capitalized, competitively advantaged companies purchased at attractive valuations in undervalued international markets offers the best defense against market uncertainty, particularly given the significant valuation gap between US and non-US equities.
Despite ongoing macro challenges, the firm takes comfort in knowing their Funds remain well positioned in financially sound enterprises in parts of the world where company stock prices are more than collateralized by underlying intrinsic value. They believe a diversified portfolio of well-capitalized, competitively advantaged companies purchased at attractive valuations offers the best defense against market uncertainty and resultant volatility.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Feb 11 2026 | 2025 Q4 | 005930.KS, BAE.L, CNHI, DHL.DE, GOOGL, IONS, J36.SI, KEMIRA.HE, MEGACPO.MX, NESN.SW, NOVN.SW, RB.PA, RHM.DE, ROG.SW, SAF.PA, TFC, TTE, U11.SI, USB, ZURN.SW | defense, dividends, global, industrials, Pharmaceuticals, value | - | Health care holdings including pharmaceutical and biotechnology companies added meaningfully to returns. Holdings such as Roche, Novartis, and Ionis Pharmaceuticals benefited from new drug approvals,… |
| Oct 31 2025 | 2025 Q3 | - | Buybacks, Dividend Yield, Europe, financials, industrials |
NESN RUI SWAN DBS SUBARU |
Dividends: Emphasis on resilient cash generation, above-average payouts, and opportunistic buybacks when shares are undervalued. Value: Adds to cyclical and mid-cap names at undemanding valuations… |
| Aug 2 2025 | 2025 Q2 | - | cash flow, defensiveness, dividends, income, Yield | - | The letter emphasizes global dividend-paying equities as a source of stable income and defensive return potential. Management highlights companies with sustainable payout ratios and conservative… |
| May 2 2025 | 2025 Q1 | - | - | - | - |
| Jan 21 2025 | 2024 Q4 | - | - | - | - |
| Sep 30 2024 | 2024 Q3 | - | - | - | - |
| Aug 2 2024 | 2024 Q2 | - | - | - | - |
| Apr 15 2024 | 2024 Q1 | - | - | - | - |
| Feb 22 2024 | 2023 Q4 | - | - | - | - |
| Jan 11 2023 | 2023 Q3 | - | - | - | - |
| Jul 31 2023 | 2023 Q2 | - | - | - | - |
| Apr 30 2023 | 2023 Q1 | - | - | - | - |
| Jan 2 2023 | 2022 Q4 | - | - | - | - |
| Nov 14 2022 | 2022 Q3 | - | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
DefenseThe team initiated a position in Curtiss-Wright, believing the company is entering a period where multiple near-term growth drivers are converging, including rising defense budgets, commercial aerospace production ramps, nuclear power plant life extensions and new builds, and submarine production. |
Defense Budgets Aerospace Nuclear Submarines |
DividendsJapanese companies paid record dividends of ¥18 trillion for fiscal year ending March 2025, a 13.8% year-over-year increase. Many major firms have adopted progressive dividend policies guaranteeing dividends will never be cut, only maintained or increased. |
Progressive Dividend Record Payouts Shareholder Returns Yield Growth | |
PharmaceuticalsEli Lilly represents a high-quality growth franchise in global healthcare, with leadership in diabetes, obesity, and neuroscience providing durable competitive advantages. The company's GLP-1 treatments continue to see demand outpace supply with additional indications on the horizon. |
Pharmaceuticals GLP1 Diabetes Obesity Healthcare | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q3 |
DividendsJapanese companies paid record dividends of ¥18 trillion for fiscal year ending March 2025, a 13.8% year-over-year increase. Many major firms have adopted progressive dividend policies guaranteeing dividends will never be cut, only maintained or increased. |
Progressive Dividend Record Payouts Shareholder Returns Yield Growth |
| 2025 Q2 |
Income |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | Fund Letters | Jay Hill | NESN | Nestlé S.A. | Consumer Staples | Food Products | Bear | Swiss Exchange | Brand, consumer staples, dividends, Food, Margins, Pricing power, valuation | Login |
| Oct 31, 2025 | Fund Letters | Jay Hill | RUI | Rubis SCA | Financials | Oil & Gas Storage & Distribution | Bull | Euronext Stock Exchange | cash flow, Distribution, dividends, Emerging markets, energy, inflation hedge, infrastructure | Login |
| Oct 31, 2025 | Fund Letters | Jay Hill | SWAN | Safran S.A. | Other | Aerospace & Defense | Bull | Euronext Stock Exchange | Aerospace, aftermarket, cash flow, Defense, Engines, growth, recovery, services | Login |
| Oct 31, 2025 | Fund Letters | Jay Hill | DBS | DBS Group Holdings Ltd. | Financials | Banks | Bull | Singapore Exchange | Asia, banking, capital return, Digitalization, dividends, resilience, ROE | Login |
| Oct 31, 2025 | Fund Letters | Jay Hill | SUBARU | Subaru Corporation | Consumer Discretionary | Automobiles | Bull | NYSE | Automobiles, capital allocation, Cost management, Demand, Electrification, Margins, recovery | Login |
| TICKER | COMMENTARY |
|---|---|
| 005930.KS | Top gainers included Samsung (+38% in U.S. dollar terms) |
| BAE.L | Defense-related holdings such as BAE Systems and Rheinmetall, which had been standout performers for much of the year, fell back a bit in the 4th Quarter. While these businesses currently benefit from secular growth in defense spending around the world, share prices have moved ahead of underlying fundamentals, and we have been modestly trimming our positions over the past few quarters. Declining stocks included BAE Systems. |
| CNHI | CNH Industrial detracted across the Funds, reflecting investors' continued concerns about the downturn of the Ag cycle and its impact on end-market demand. CNH remains significantly undervalued in our view, and we are adding to our position opportunistically. We took advantage of a pricing opportunity and added to CNH Industrial, which is now a top 10 holding in all four funds. |
| DHL.DE | DHL Group reported quarterly results that beat profit expectations (despite a slight revenue dip), driven by cost efficiencies and e-commerce growth. |
| GOOGL | In the third quarter, Google, Kairos Power, and the Tennessee Valley Authority announced a major collaboration centered on a novel power purchase agreement. Google followed this announcement with another significant step forward. On October 27, Google and NextEra Energy announced plans to restart the Duane Arnold Energy Center. |
| IONS | Holdings such as Roche, Novartis, and Ionis Pharmaceuticals benefited from new drug approvals, steady and growing earnings, and business models that continue to generate cash through a wide range of economic conditions. |
| J36.SI | our Asian investments performed strongly with Alibaba and Jardine Matheson up 63% |
| NESN.SW | We see now as an opportune time to own a company that possesses world-leading brands in consumer categories we believe have a favourable growth outlook in the long run. Nestlé's comprehensive pricing architecture through umbrella brands Nescafé and Nespresso means the portfolio should be well-positioned to capture spending shifts up and down the price ladder. In pet foods, Nestlé also possesses category leaders in its Purina line. We see both coffee and pet care as attractive categories that are more experiential and less commoditised relative to other staples. Over recent quarters, Nestlé was able to deliver positive volume growth in coffee despite pushing through high-single-digit percentage price increases. Scale matters as Nestlé is the world's largest provider of packaged coffee and among the top pet food producers globally. |
| NOVN.SW | Holdings such as Roche, Novartis, and Ionis Pharmaceuticals benefited from new drug approvals, steady and growing earnings, and business models that continue to generate cash through a wide range of economic conditions. We also trimmed several larger holdings, including Roche, Novartis, Safran, and TotalEnergies, whose stock prices had approached underlying intrinsic value. |
| RHM.DE | The top three contributors to this underperformance came from Rheinmetall (German Defense). The top three contributors to this outperformance came from Rheinmetall (German Defense) |
| ROG.SW | Top gainers among the Fund's holdings included Roche (+27%) |
| SAF.PA | Safran, buoyed by robust aerospace and aftermarket parts demand, reported record profits for the prior year in early 2025. As global air traffic continued to recover and air carriers ramped up maintenance projects, the company saw stronger aftermarket growth and converted operational efficiency gains into higher earnings, prompting management to raise full-year guidance for 2025. |
| TFC | This preferred stock position was called during the period. |
| TTE | Global oil & gas producer and distributor and low carbon electricity supplier |
| USB | Select holdings in banking (US Bank) detracted from returns |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||